SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the first of two pivotal phase 3 clinical trials examining the safety and efficacy of prulifloxacin for the treatment of travelers’ diarrhea. Travelers’ diarrhea is characterized by diarrhea along with other related symptoms including nausea, vomiting, abdominal pain or cramping, and fecal urgency.
